Welcome to our dedicated page for Harrow Health SEC filings (Ticker: HROW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Harrow, Inc. (HROW) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. Harrow is an ophthalmic-focused pharmaceutical company whose common stock trades on the Nasdaq Stock Market, and its filings offer detailed information about its financial condition, capital structure, and material corporate events.
Harrow’s current reports on Form 8-K include disclosures about quarterly financial results, investor presentations, credit agreements, leadership changes at subsidiaries, and business development transactions. For example, recent 8-K filings describe the announcement of financial results for the period ended September 30, 2025, the entry into and terms of a senior secured revolving credit facility with a commercial bank, and the agreement to acquire, and subsequent completion of the acquisition of, Melt Pharmaceuticals, Inc., a clinical-stage company developing non-opioid, non-IV sedation therapies.
The company’s filings also document capital markets and debt activities. Harrow has reported the pricing of senior unsecured notes due 2030 in a private offering and related plans to use the proceeds to repay existing debt and redeem previously issued senior notes. Separate Form 25 filings by the Nasdaq Stock Market LLC show the removal from listing and registration of Harrow’s 8.625% senior notes due 2026 and 11.875% senior notes due 2027.
Through Stock Titan, users can follow Harrow’s 10-K annual reports, 10-Q quarterly reports, and 8-K current reports as they are made available on EDGAR. AI-powered summaries help explain the key points in these documents, including revenue trends, operating results, debt arrangements, and the terms of material agreements such as merger agreements and credit facilities. The filings page also surfaces information relevant to equity and debt investors, including unregistered sales of equity securities disclosed in connection with milestone-based consideration for acquisitions.
For investors analyzing Harrow’s ophthalmic and procedural sedation strategy, the SEC filings provide primary-source detail on transaction structures, milestone obligations, and financial covenants. Stock Titan’s tools are designed to make these complex filings easier to review by highlighting important sections and presenting concise explanations of the underlying disclosures.
Harrow, Inc. has signed an Agreement and Plan of Merger to acquire all remaining equity of Melt Pharmaceuticals, a company in which Harrow already owns about 45% and holds a royalty on MELT-300. Because Harrow executives and directors also hold Melt equity and one serves on Melt’s board, the deal terms were negotiated and approved by an independent board committee, which obtained its own legal counsel and a fairness opinion.
At closing, Harrow will pay approximately $4.3 million in cash, with additional contingent payments tied to the MELT-300 program and its commercial performance. Upon FDA approval of MELT-300, Harrow would pay about $87.2 million in cash; upon CMS coding and reimbursement (including pass-through status and a J-Code or similar), it would issue roughly 1,112,000 Harrow common shares. One-time cash payments of up to about $261.0 million may be owed if annual net sales milestones between $100 million and $1.0 billion are achieved by December 31, 2035. Closing remains subject to customary conditions, including approval by Melt stockholders.
Harrow, Inc. (HROW) filed a Form 4 disclosing a stock option grant to Chief Accounting Officer Randall E. Pollard. On 09/01/2025 Mr. Pollard was granted an option to purchase 30,000 shares of common stock at an exercise price of $39 per share. The option expires on 09/01/2035 and is exercisable according to a vesting schedule: 25% at the one-year anniversary and the remainder vesting in 12 equal quarterly installments, becoming fully vested and exercisable on 09/01/2029. The filing was signed by an attorney-in-fact on 09/09/2025.
Randall E. Pollard, the Chief Accounting Officer of Harrow, Inc. (HROW), filed an initial Form 3 reporting that he does not beneficially own any securities of the company. The event requiring the statement is dated
Harrow, Inc. disclosed that it has priced an offering of
The company announced the pricing through a press release dated September 8, 2025, which is incorporated by reference as an exhibit. The disclosure emphasizes that this communication is not an offer or solicitation to buy or sell securities in any jurisdiction where such activity would be unlawful.
Harrow, Inc. outlined a major financing and strategic plan centered on a proposed private offering of
Harrow intends to use net proceeds from the 2030 notes to redeem its 8.625% Senior Notes due 2026 and 11.875% Senior Notes due 2027, prepay an Oaktree loan, pay related exit costs, and for general corporate purposes. It has issued a conditional full redemption notice for the 2027 notes at 102% of principal plus accrued interest and expects to call the 2026 notes at 100% plus a make-whole and accrued interest, both funded from the offering. Separately, Harrow signed a non-binding indication of interest to acquire the remaining equity in Melt Pharmaceuticals for about
Harrow, Inc. reported leadership changes and corporate governance updates. The board appointed longtime finance executive Andrew R. Boll, currently Chief Financial Officer and Secretary, to also serve as President, effective August 21, 2025, with no changes to his compensation.
The company also appointed Randall E. Pollard as Chief Accounting Officer, effective September 1, 2025. His offer includes a $400,000 annual base salary, a target cash bonus equal to 40% of salary, relocation support, and eligibility for six months of severance after 12 months of service. The board approved amended and restated bylaws designating the Chief Executive Officer as principal executive officer, clarifying officer roles, updating titles, and making technical edits.
Harrow, Inc. reported stronger product sales and improved operating performance for the quarter and six months ended June 30, 2025. Product sales for the three months were $63,657,000 compared with $48,871,000 a year earlier, and total revenues for the three months were $63,742,000 versus $48,939,000. Gross profit for the quarter was $47,512,000, driving a GAAP net income of $4,995,000 for the three months ended June 30, 2025, compared with a net loss of $6,473,000 in the prior-year quarter.
For the six months ended June 30, 2025, total revenues were $111,573,000 versus $83,526,000 a year earlier and the company reported a net loss of $12,785,000, an improvement from a $20,038,000 loss in the prior-year period. Cash and cash equivalents increased to $52,963,000 and operating activities provided $18,865,000 of cash during the six months. Material near-term financing items exist: the Oaktree Loan ($107,500,000 principal) and the 2026 Notes ($75,000,000) mature in January and April 2026, and management is pursuing refinancing or asset sales but notes there is no assurance of success, stating these maturities could raise substantial doubt about the company’s ability to continue as a going concern.